|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 3/14/13 DelMar Pharmaceuticals, Inc. 8-K/A:1,2,3 1/25/13 8:2.7M MDM Corp Elec Fi… Inc/FA |
Document/Exhibit Description Pages Size 1: 8-K/A Delmar Pharmaceuticals, Inc Form 8-K/A HTML 1.09M 3: EX-10.10 Material Contract HTML 15K 4: EX-10.11 Material Contract HTML 26K 5: EX-10.12 Material Contract HTML 75K 6: EX-10.13 Material Contract HTML 76K 7: EX-10.14 Material Contract HTML 76K 8: EX-10.15 Material Contract HTML 73K 2: EX-10.9 Material Contract HTML 152K
|
A.
|
DelMar has entered into a letter of intent with Berry Only, Inc. (BRRY), a public company, and engaged the services of an investment banker to undertake a Reverse Take-Over and financing that will result in DelMar becoming a publicly traded company under which BRRY shall change its name to DelMar Pharmaceuticals, Inc.;
|
|
B.
|
The investment banker has requested that the Parties amend the Agreement and the Parties have agreed to enter into this Amendment to record the terms on which the Agreement shall be amended, in accordance with Article 11.8 of the Agreement; and
|
|
C.
|
All capitalized terms not defined herein have the meaning ascribed thereto in the Purchase and Patent Assignment Agreement dated September 20, 2010.
|
|
1.
|
The Royalty under Article 4.1 of the Agreement shall be reduced to 5%. For clarity, Article 4.1 shall read: “On a Product-by-Product and country-by-country basis, during the applicable Royalty Term, Del Mar will pay Valent royalties based upon the Net Sales by Del Mar and its Affiliates for each product. Subject to Section 4.4, the royalty rate for each Product and on a Product-by-Product basis for Net Sales made by Del Mar and its Affiliates will be 5%.
|
|
2.
|
The reduction in the royalty under Article 4.1 of the Agreement shall be subject to the following terms and conditions:
|
|
B.
|
The issuance of 1,150,000 shares of Berry Only, Inc. (or DelMar Pharmaceuticals, Inc. following the name change) to Valent.
|
| VALENT TECHNOLOGIES, LLC | DEL MAR PHARMACEUTICALS (BC) LTD. | |||
|
/s/ Dennis Brown
|
/s/ Jeffrey Bacha
|
|||
|
Jeffrey Bacha, President & CEO
|
||||
|
|
|
| This ‘8-K/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/14/13 | CORRESP | ||
| For Period End: | 1/25/13 | 3, 3/A, 8-K, 8-K/A | ||
| 9/20/10 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/27/23 Kintara Therapeutics, Inc. S-1/A 12:1.2M Donnelley … Solutions/FA 10/24/23 Kintara Therapeutics, Inc. S-1/A 20:2.4M Donnelley … Solutions/FA 10/04/23 Kintara Therapeutics, Inc. S-1 13:1.1M Donnelley … Solutions/FA 9/18/23 Kintara Therapeutics, Inc. 10-K 6/30/23 75:12M Donnelley … Solutions/FA 9/27/22 Kintara Therapeutics, Inc. 10-K 6/30/22 79:15M Donnelley … Solutions/FA 9/28/21 Kintara Therapeutics, Inc. 10-K 6/30/21 79:13M ActiveDisclosure/FA 9/18/20 Kintara Therapeutics, Inc. 10-K 6/30/20 71:9.9M ActiveDisclosure/FA |